Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.09.2012 | short review

ASH update 2011: chronic lymphocytic leukemia and indolent lymphoma

verfasst von: Michael Steurer, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

At the annual meeting of the American Society of Hematology (ASH) 2011, the focus in the field of chronic lymphocytic leukemia (CLL) and indolent lymphomas was again rather the translation of basic research results into early clinical trials than introducing new treatment standards. Although still at an early phase in the process of drug development, the results achievable with the Bruton’s tyrosine kinase inhibitor ibrutinib (formerly PCI-32765) in CLL and mantle cell lymphoma (MCL) are promising. Concerning clinical practice, new or updated results of trials exploring lenalidomide as well as new monoclonal antibodies (obinutuzumab, ofatumumab) in CLL/indolent lymphoma underscore the clinical value of these drugs, but their definite place in the respective treatment algorithm still needs to be defined.
Vorheriger Artikel Treating T-cell lymphoma: is there a light at the end of the tunnel?
Nächster Artikel Brief update on recent developments in CML
Literatur
1.
Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164–74.PubMedCrossRef
2.
Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1756–65.PubMedCrossRef
3.
Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter phase II trial of the German CLL study group (GCLLSG). Blood (ASH Annual Meeting Abstracts). 2009;114:205.
4.
Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27:4378–84.PubMedCrossRef
5.
Herman SE, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010;116:2078–88.PubMedCrossRef
6.
Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011;117:591–4.PubMedCrossRef
7.
Sharman J, de Vos S, Leonard JP, et al. A phase 1 study of the selective phosphatidylinositol 3-kinase-delta (PI3Kd) inhibitor, CAL-101 (GS-1101), in combination with rituximab and/or bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood (ASH Ann Meeting Abstracts). 2011;118:1787.
8.
Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463:88–92.PubMedCrossRef
9.
O’Brien S, Burger JA, Blum KA, et al. The Bruton’s tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): follow-up of a phase Ib/II study. Blood (ASH Annual Meeting Abstracts). 2011;118:983.
10.
Ponader S, Buggy J, O’Brien S, et al. Bruton’s tyrosine kinase inhibitor PCI-32765 abrogates BCR- and nurselike cell-derived activation of CLL cells in vitro and in vivo. Blood (ASH Annual Meeting Abstracts). 2010;116:45.CrossRef
11.
Egle A, Steurer M, Gassner F, et al. A combination of fludarabine/rituximab with escalating doses of lenalidomide in previously untreated chronic lymphocytic leukemia (CLL): the REVLIRIT CLL5 AGMT phase I/II study, clinical and exploratory analyses of induction results. Blood (ASH Annual Meeting Abstracts). 2011;118:292.
12.
Ferrajoli A, O’Brien S, Wierda WG, et al. Combination therapy with ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL): results of a phase II trial. Blood (ASH Annual Meeting Abstracts). 2011;118:1788.
13.
Wang L, Martin P, Blum KA, et al. The Bruton’s tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): preliminary results of a phase II trial. Blood (ASH Annual Meeting Abstracts). 2011;118:442.
14.
Press OW, Unger JM, Rimsza LM, et al. A phase III randomized intergroup trial (SWOG S0016) of CHOP chemotherapy plus rituximab Vs. CHOP chemotherapy plus iodine-131-Tositumomab for the treatment of newly diagnosed follicular non-Hodgkin’s lymphoma. Blood (ASH Annual Meeting Abstracts). 2011;118:98.CrossRef
15.
Fowler NH, Kahanic SP, Forero A, et al. Results of a phase II study with bendamustine and ofatumumab in untreated indolent B-Cell non-Hodgkin’s lymphoma. Blood (ASH Annual Meeting Abstracts). 2011;118:778.CrossRef
16.
Sehn LH, Goy A, Offner FC, et al. Randomized phase II trial comparing GA101 (Obinutuzumab) with rituximab in patients with relapsed CD20 indolent B-Cell non-Hodgkin lymphoma: preliminary analysis of the GAUSS study. Blood (ASH Annual Meeting Abstracts). 2011;118:269.
Metadaten
Titel
ASH update 2011: chronic lymphocytic leukemia and indolent lymphoma
verfasst von
Michael Steurer, MD
Publikationsdatum
01.09.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0041-0

Weitere Artikel der Ausgabe 3/2012

News from the Neuro-Oncology front

  • editorial

ASH 2011: “Real generosity toward the future lies in giving all to the present”

  • editorial

New developments in MDS

  • short review

ASH 2011—current developments in AML

  • short review

Treating T-cell lymphoma: is there a light at the end of the tunnel?

  • short review

Drug therapy for recurrent, progressive, atypical, and malignant meningiomas

  • short review